Teva debuts generic Lialda in USA

27 March 2018

Israeli generics giant Teva Pharmaceutical Industries (NYSE: TEVA) late Monday announced the launch of a generic version of Ireland-headquartered Shire’s (LSE: SHP) Lialda(mesalamine) delayed-release tablets, 1.2g, in the USA.

Mesalamine delayed-release tablets are indicated for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Mesalamine delayed-release tablets, 1.2g had annual sales of around $1.11 billion in the USA, according to IQVIA data as of January 2018.

"The launch of mesalamine is a significant addition to Teva's generic portfolio," said Brendan O'Grady, executive vice president and head of North America Commercial at Teva. "With more than a million people in the US estimated to suffer from inflammatory bowel diseases, including ulcerative colitis, this is an important and more affordable generic treatment option for our customers," he noted.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK